MedDataX Logo

Chemical Shift Encoding-based Water-fat Magnetic Resonance Imaging in Spinal Tumors

NCT ID: NCT05631002

Last Updated: 2022-11-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-08-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fat composition of the spinal tumors is positively correlated with classification and differential diagnosis of benign and malignant tumors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Chemical shift encoding-based water-fat magnetic resonance imaging (MRI) is a non-invasive method that provides quantitative information about the biochemical water-fat composition of bone marrow and skeletal muscle in vivo.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spinal Tumor Bone Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with benign spinal tumor

Chemical shift encoding-based water-fat MRI

Intervention Type DIAGNOSTIC_TEST

Chemical shift encoding-based water-fat magnetic resonance imaging (MRI): a non-invasive method

Patients with intermediate spinal tumor

Chemical shift encoding-based water-fat MRI

Intervention Type DIAGNOSTIC_TEST

Chemical shift encoding-based water-fat magnetic resonance imaging (MRI): a non-invasive method

Patients with malignant spinal tumor

Chemical shift encoding-based water-fat MRI

Intervention Type DIAGNOSTIC_TEST

Chemical shift encoding-based water-fat magnetic resonance imaging (MRI): a non-invasive method

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Chemical shift encoding-based water-fat MRI

Chemical shift encoding-based water-fat magnetic resonance imaging (MRI): a non-invasive method

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pathological biopsy of a patient with diagnosed spinal tumor lesion, and preoperative examination Chemical shift encoding-based water-fat MRI was performed.

Exclusion Criteria

* Recurrent neoplasms; Lesion diameter \< 1 cm; Poor image quality.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Peking University Third Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ning Lang

Role: STUDY_CHAIR

Peking University Third Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Peking University third hospital

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Qizheng Wang

Role: CONTACT

Phone: 13161593501

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ning Lang

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

M2022403

Identifier Type: -

Identifier Source: org_study_id